Meta-Analysis of Cytochrome P-450 2C9 Polymorphism and Colorectal Cancer Risk

Shuo Liang1*, Jingsong Hu2*, Weijun Cao1*, Sanjun Cai2*

1 Department of Respiratory, Pulmonary Hospital of Shanghai, Tongji University School of Medicine, Shanghai, People’s Republic of China, 2 Department of Colorectal Cancer, Shanghai Cancer Center, Fudan University School of Medicine, Shanghai, People’s Republic of China

Abstract

Background: CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes which play a central role in activating and detoxifying many carcinogens and endogenous compounds thought to be involved in the development of colorectal cancer (CRC). In the past decade, the relationship between CYP2C9 common polymorphisms (R144C and I359L) and CRC has been reported in various ethnic groups; however, these studies have yielded contradictory results. To investigate this inconsistency, we performed this meta-analysis.

Methods: Databases including Pubmed, EMBASE, Web of Science and China National Knowledge Infrastructure (CNKI) were searched to find relevant studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association.

Results: A total of 13 articles involving 9,463 cases and 11,416 controls were included. Overall, the summary odds ratio of CRC was 0.98 (95% CI: 0.89–1.06) and 0.99 (95% CI: 0.87–1.14) for CYP2C9 144C and 359L alleles, respectively. No significant results were observed using dominant or recessive genetic model for these polymorphisms. In the stratified analyses according to ethnicity and sex, no evidence of any gene-disease association was obtained.

Conclusions: This meta-analysis suggests that the CYP2C9 may not be associated with colorectal cancer development.

Introduction

Colorectal cancer (CRC), second only to lung cancer, is a major cause of cancer death in the western world [1]. Despite much investigation, the causes are not yet fully understood. The marked regional differences of CRC incidence rates implicate the combined influence of genetic predisposition and local environmental factors such as local carcinogen exposure and diet [2–4].

Diverse xenobiotic-metabolizing enzymes that are capable of activating carcinogens and mutagens are expressed in human intestinal epithelium [5,6]. Among them, cytochrome P450 (CYP) enzymes play a key role in the metabolism of xenobiotics. The CYP2C enzyme subfamily accounts for about 20% of the total CYP enzymes in human liver, CYP2C9 being the most abundant [7,8]. CYP2C9 is involved in both the activation of dietary carcinogens and mutagens, liver metabolism and local metabolism in intestinal epithelium may occur. Since CRC risk is epidemiologically linked to dietary habits, CYP2C9 gene may be a good candidate for genetics studies on CRC. Several important single nucleotide polymorphisms have been identified in the CYP2C9 gene. Two coding-region CYP2C9 variants (Arg144Cys and Ile359Leu) encode three common polymorphisms: the wild-type CYP2C9*1 allele, and two variant *2, and *3 alleles identified in Caucasians [9–12]. In vitro analyses have shown substantial variation in CYP2C9 metabolic capacity with the variant *2 and *3 alleles associated with 30% and 80% lower enzymatic activity, respectively, when compared with the wild-type *1 allele [13,14].

Despite the biological plausibility of CYP2C9 functional polymorphisms as a modulator of CRC susceptibility, previously inconsistent results have appeared in the literature. Published studies have generally been restricted in terms of sample size and ethnic diversity, and individual studies may have insufficient power to achieve a comprehensive and reliable conclusion. We therefore performed a meta-analysis of the published studies to clarify this inconsistency and to establish a comprehensive picture of the relationship between CYP2C9 and CRC.

Materials and Methods

Literature Search Strategy

Genetic association studies published before the end of Apr. 2012 on CRC and polymorphisms within CYP2C9 gene were
identified through a search of PubMed, Web of Science, EMBASE and CNKI (Chinese National Knowledge Infrastructure) without language restrictions. Search term combinations were keywords related to the CYP2C9 gene (e.g., “cytochrome p450 2C9”, “cytochrome p450 IIc9”, and “CYP2C9”) in combination with words related to CRC (e.g., “colorectal”, “colon”, “rectal” combined with “cancer” or “carcinoma” or “tumor” or “neoplasms”) and polymorphism or variation. The search was supplemented by reviews of reference lists for all relevant studies and review articles. The major inclusion criteria were (a) original publications, (b) case-control or cohort studies and (c) genotype distribution information or odds ratio (OR) with its 95% confidence interval (CI) and P-value. The major reasons for exclusion of studies were (a) overlapping data and (b) case-only studies, family-based studies and review articles.

### Data Extraction

For each study, the following data were extracted independently by two authors: first author’s surname, year of publication, diagnosis criterion, age, sex, ethnicity, Hardy–Weinberg equilibrium (HWE) status, genotyping method, source of control, total number of cases and controls and genotype frequency in cases and controls. The results were compared, and disagreements were discussed among all authors and resolved with consensus.

### Statistical Methods

Odds ratio (OR) with 95% confidence intervals (CIs) was used to assess the strength of association between the CYP2C9 gene polymorphism and CRC risk. The per-allele OR of the risk allele of these polymorphisms mentioned above was compared between cases and controls. Additional pooled estimates were also given with corresponding results under dominant and recessive genetic models. Cochran’s chi-square-based Q statistic test was performed in order to assess possible heterogeneity between the individual studies and thus to ensure that each group of studies was suitable for meta-analysis. ORs were pooled according to the method of DerSimonian and Laird that takes into account the variation between studies, and 95% CI were constructed using Woolf’s method [15,16]. The Z test was used to determine the significance of the pooled OR. Sensitivity analyses were performed to assess the stability of the results, namely, a single study in the meta-analysis was deleted each time to reflect the influence of the corresponding results under different genetic models. Using random effect model, the per-allele overall OR of the C variant for CRC was 0.98 [95% CI: 0.89–1.06; $P(Q) = 0.58$; $P(Z) = 0.04$], with corresponding results under dominant and recessive genetic models of 0.94 [95% CI: 0.85–1.04; $P(Q) = 0.21$; $P(Z) = 0.05$, Figure 2] and 1.22 [95% CI: 1.00–1.47; $P(Z) = 0.05$; $P(Q) = 0.46$], respectively.

Analysis restricted to the 12 studies conducted in Caucasian population (total, 9077 cases and 10822 controls), yielded an per-allele OR for C variant of 0.98 [95% CI: 0.90–1.07; $P(Z) = 0.16$; $P(Q) = 0.09$]. Similar results were also found using dominant [OR = 0.94, 95% CI: 0.86–1.04; $P(Z) = 0.25$; $P(Q) = 0.04$] or recessive [OR = 1.24, 95% CI: 1.00–1.52; $P(Q) = 0.05$; $P(Q) = 0.39$] genetic model. The polymorphism was found to occur in frequencies consistent with HWE in the control populations for these studies. The data on genotypes of the polymorphism among cases stratified by the sex were available in 5 studies. The per-allele OR was 1.06 [95% CI: 0.75–1.50; $P(Z) = 0.73$; $P(Q) = 0.02$] in woman compared to 0.91 [95% CI: 0.71–1.17; $P(Z) = 0.43$; $P(Q) = 0.15$] in men. Similarly, no statistically significant results were observed under dominant and recessive genetic models.

### Association of R144C Polymorphism with CRC

Overall, there was no evidence of an association between the increased risk of CRC and the R144C variant in different genetic models when all eligible studies were pooled into the meta-analysis. Using random effect model, the per-allele overall OR of the R variant for CRC was 0.99 [95% CI: 0.91–1.17; $P(Z) = 0.97$; $P(Q) = 0.02$] in woman and 0.91 [95% CI: 0.71–1.17; $P(Z) = 0.43$; $P(Q) = 0.15$] in men. Similarly, no statistically significant results were observed under dominant and recessive genetic models.

### Association of I359L Polymorphism with CRC

Overall, the per-allele OR of the I359L polymorphism for CRC was 0.99 [95% CI: 0.87–1.14; $P(Z) = 0.94$; $P(Q) = 0.03$], with corresponding results under dominant and recessive genetic models of 1.00 [95% CI: 0.86–1.16; $P(Z) = 0.97$; $P(Q) = 0.02$] and 0.87 [95% CI: 0.41–1.88; $P(Z) = 0.73$; $P(Q) = 0.21$], respectively. One study found to be deviated from HWE, negative results still maintained after excluding it [L allele: OR = 1.02, 95% CI = 0.90–1.16, $P(Z) = 0.75$; $P(Q) = 0.07$; domi-
Table 1. Characteristics of the studies included in the meta-analysis.

| Study          | Year | Ethnicity     | Case                      | Control          | No. of case/control | Gender distribution in cases/controls (male %) | Control source | Genotyping method |
|----------------|------|---------------|---------------------------|------------------|---------------------|-----------------------------------------------|----------------|-------------------|
| Martínez [19]  | 2001 | Spanish       | Histology confirmed      | Healthy          | 110/123             | 53.0/53.0                                      | PB             | RFLP              |
| Chan [20]      | 2004 | American      | Histology confirmed      | Healthy          | 339/350             | 0/0                                           | PB             | Taqman            |
| Tranah [21]    | 2005 | American      | CRC patients             | Healthy          | 416/825             | 0/0                                           | PB             | Taqman            |
| Landi [22]     | 2005 | Spanish       | CRC patients             | Cancer free      | 364/324             | NA/NA                                         | HB             | Sequencing        |
| McGreavey [23] | 2005 | British       | ICD-9                    | Healthy          | 490/592             | 61.0/54.0                                      | PB             | Taqman            |
| Samowitz [24]  | 2006 | American      | ICD-9                    | Healthy          | 2295/2903           | 57.1/54.6                                      | PB             | RFLP, TaqMan      |
| Liao [25]      | 2007 | Chinese       | CRC patients             | Healthy          | 284/483             | 54.5/53.6                                      | PB             | Sequencing        |
| Küry [26]      | 2007 | French        | CRC patients             | Healthy          | 1013/1118           | 62.0/54.0                                      | PB             | Taqman            |
| Cotterchio [27]| 2008 | Canadian      | ICD-9                    | Healthy          | 834/1249            | NA/NA                                         | PB             | Taqman            |
| Buyukdogan [28]| 2009 | Turkish       | CRC patients             | Healthy          | 77/78               | 52.0/53.0                                      | PB             | RT-PCR            |
| Northwood [29] | 2010 | British       | Colonoscopy confirmed    | Healthy          | 308/296             | 71.3/58.8                                      | PB             | Taqman            |
| Cleary [30]    | 2010 | Canadian      | ICD-9                    | Healthy          | 1165/1292           | 41.0/56.0                                      | PB             | Taqman            |
| Sainz [31]     | 2011 | German        | CRC patients             | Healthy          | 1768/1783           | 58.6/59.8                                      | PB             | KASP assay        |

ICD: International Classification of Diseases, NA: not available, HB: hospital-based, PB: population-based.

doi:10.1371/journal.pone.0049134.t001

Figure 2. Forest plot from the meta-analysis of colorectal cancer and CYP2C9 R144C polymorphism using dominant genetic model.
doi:10.1371/journal.pone.0049134.g002
nant model: OR = 1.03, 95% CI = 0.89 – 1.18, P(Z) = 0.70, P(Q) = 0.03; recessive model: OR = 0.87, 95% CI = 0.40 – 1.88, P(Z) = 0.73, P(Q) = 0.21].

The meta-analysis included 11 studies (7,374 cases and 8,734 controls) in Caucasian population. The Q-test of heterogeneity was not significant in the contrasts of L versus I, dominant, and recessive genetic models. No statistically significant association was established for the CYP2C9 I359L polymorphism in Caucasian population (L allele: OR = 0.95, 95% CI = 0.87 – 1.05, P = 0.33; dominant model: OR = 0.96, 95% CI = 0.86 – 1.06, P = 0.40; recessive model: OR = 0.87, 95% CI = 0.40 – 1.88, P = 0.73).

When studies were stratified for sex (6 studies), no significant risks were found among men in all genetic models [L allele: OR = 1.22, 95% CI = 0.66 – 2.28, P(Z) = 0.54; dominant model: OR = 1.24, 95% CI = 0.64 – 2.41, P(Z) = 0.52; recessive model: OR = 0.69, 95% CI = 0.11 – 4.11, P(Z) = 0.68]. Similar results were also found in the woman [L allele: OR = 1.21, 95% CI = 0.94 – 1.57, P(Z) = 0.14; dominant model: OR = 1.22, 95% CI = 0.92 – 1.60, P(Z) = 0.16; recessive model: OR = 2.03, 95% CI = 0.51 – 8.15, P(Z) = 0.32].

Sensitivity Analyses and Publication Bias

A single study involved in the meta-analysis was deleted each time to reflect the influence of the individual dataset to the pooled ORs, and the corresponding pooled ORs were not qualitatively altered (data not shown). Begg’s funnel plot and Egger’s test were performed to access the publication bias of the literatures. The shape of the funnel plots was symmetrical for the two polymorphisms (Figure S1 and S2). The statistical results still did not show publication bias in these studies for R144C (Egger’s test: P = 0.86) and I359L (Egger’s test: P = 0.97).

Discussion

Large sample and unbiased epidemiological studies of predisposition genes polymorphisms could provide insight into the in vivo relationship between candidate genes and complex diseases. The involvement of CYP2C9 enzyme in the metabolism of xenobiotics could underlie the mechanism responsible for the association of CYP2C9 genotype and colorectal cancer. So far, many studies had focused on association between CYP2C9 polymorphism and CRC, but the results were still unclear. This is the first comprehensive meta-analysis examined the two functional polymorphism (R144C and I359L) of CYP2C9 and the relationship to susceptibility for CRC. Its strength was based on the accumulation of published data giving greater information to detect significant differences. In total, the meta-analysis involved 14 studies for CRC which provided 9,463 cases and 11,416 controls.

In this large-scale meta-analysis, the combined evidence suggested that CYP2C9 *2 and *3 polymorphism did not contribute to the development of CRC. However, CRC is a
complex disease, and both environmental and genetic factors are involved in the development of CRC. There are some possible reasons for the inconsistent results in early reports. Firstly, ethnic differences may attribute to these different results, since the distributions of the CYP2C9 polymorphism were different between various ethnic populations. For instance, the frequencies of CYP2C9*2 polymorphism allele differs from 0.6% in Chinese population [32], 11% in British populations [29], to 18% in Caucasian-American [21]. On the other hand, study design or small sample size or some environmental factors may affect the results. Most of these studies did not consider most of the important environmental factors. It is possible that variation at this locus has modest effects on CRC, but environmental factors may predominate in the progress of CRC, and mask the effects of this variation. Specific environmental factors like lifestyle and cigarette smoking have already been well studied in recent decades [21,26]. The unconsidered factors mixed together may cover the role of CYP2C9 polymorphism. Thus, even if the variation has a causal effect on CRC, it may take a long time to be observed.

CYP2C9*3 encodes a protein with approximately 5–30% of the activity of the common reference allele [33], and it could therefore be hypothesized that CYP2C9*3 allele carriers have reduced carcinogen activating ability and thus reduced disease risk. However, the increased CRC risk associated with CYP2C9*2 genotype in earlier studies suggests that the enzyme may play a more important role in detoxification of carcinogens. The CYP2C9*3 association data should therefore be considered as a hypothesis-generating observation, which requires replication in larger independent cohorts. We also acknowledge that our study is not sufficiently powered to investigate the influence of low frequency alleles such as CYP2C9*3 (few CYP2C9*3/*3 homozygotes were present in our study) even by pooling all available data together. It is also important to note that CYP2C9, like many other P450 enzymes is inducible by a variety of structurally diverse chemicals, as part of the body’s adaptive response to environmental challenge [34]. It will therefore be of interest in future studies to investigate the extent of individuality in CYP2C9 protein expression and activity (and the expression of other inducible drug metabolizing enzymes), to assess the extent to which CYP2C9 phenotype influences CRC risk.

In interpreting the results, some limitations of this meta-analysis should be addressed. Firstly, our results were based on unadjusted estimates, while a more precise analysis should be conducted if all individual raw data were available, which would allow for the adjustment by other co-variants including age, drinking status, cigarette consumption, and other lifestyle. Secondly, the subgroup meta-analyses considering sex different between CYP2C9 polymorphisms and CRC risk, was performed on the basis of a fraction of all the possible data to be pooled, so selection bias may have occurred and our results may be overinflated. Nevertheless, the total number of subjects included in this part of the analysis comprises the largest sample size so far. Thirdly, only published studies were included in this meta-analysis. Therefore, publication bias may have occurred, even though the use of a statistical test did not show it.

To conclude, our meta-analysis did not support an association of the R144C and I359L polymorphism of CYP2C9 with CRC. The importance of these polymorphisms as a predictor of the risk of CRC is probably very small and the screening utility of this genetic variant in asymptomatic individuals may not be warranted. It is also known that the pathogenesis of CRC is complex and polygenic in the vast majority of patients, with several genes, each with a small to moderate effect, acting individually, together or in association with important environmental determinants. Larger studies of different ethnic populations, especially strict selection of patients, well-matched controls, are needed to confirm our findings.

Supporting Information

Figure S1 Begg’s funnel plot of CYP2C9 R144C polymorphism and colorectal cancer. (TIF)

Figure S2 Begg’s funnel plot of CYP2C9 I359L polymorphism and colorectal cancer. (TIF)

Checklist S1 (DOC)

Author Contributions

Conceived and designed the experiments: WJC SjC.Performed the experiments: SL JhH. Analyzed the data: SL JhH. Contributed reagents/materials/analysis tools: SL JhH. Wrote the paper: WJC SjC.

References

1. Center MM, Jemal A, Smith RA, Ward E (2009) Worldwide variations in colorectal cancer. CA Cancer J Clin 59: 366–378.
2. Gertig DM, Hunter DJ (1998) Genes and environment in the etiology of colorectal cancer. Semin Cancer Biol 8: 283–290.
3. Marchand LL (1999) Combined influence of genetic and dietary factors on colorectal cancer incidence in Japanese Americans. J Natl Cancer Inst Monogr 26: 101–105.
4. Laffontre MJ, Castreud X, Trias M, et al. (2000) NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 21: 1813–1819.
5. Windmill KF, McKinnon RA, Zhu X, Gaedigk A, Grant DM, McManus ME, Minchin RF (1994) Expression of monomorphic and polymorphic human CYP2C subfamily. Pharmacogenetics 4: 285–299.
6. Ilett KF, Ingram DM, Carpenter DS, Teitel CH, Lang NP, Kadlubar FF, Minchin RF (1994) Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol 47: 914–917.
7. Goldstein JA, De Moraes SM (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285–299.
8. Inoue K, Yamakazi H, Iinai K, Akaasa S, Gurgenich FP, Shimada T (1997) Relationship between CYP2C9 and CYP2C9 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4’-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7: 103–113.
9. Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD (2000) Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-2 inhibitor. J Pharmacol Exp Ther 293: 453–459.
10. Tang C, Shou M, Rodrigues AD (2000) Substrate-dependent effect of acetanilide on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity. Drug Metab Dispos 28: 567–572.
11. Tang C, Shou M, Rushmore TH, et al. (2001) In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: Correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 11: 223–235.
12. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E (2002) Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 54: 423–429.
13. Takanashi K, Tanaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K (2000) CYP2C9 I359L and Leu359 variants: Enzyme kinetic study with seven substrates. Pharmacogenetics 10: 95–104.
14. Cropp CL, Miller VP (1997) The R144C change in the CYP2C92 allele alters interaction of the biotyochrome P450 with NADPH: Cytochrome P450 oxidoreductase. Pharmacogenetics 7: 203–210.
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
16. Woolf B (1955) On estimating the relation between blood group and disease. S3: 197–207.
17. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
18. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1091.
19. Martinez C, Garcia-Martín E, Ladero JM, Sastre J, Garcia-Gamito F, et al. (2001) Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 22: 1323–1326.
20. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS (2004) A prospective study of genetic polymorphisms in the cytochrome P450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol 2: 704–712.
21. Tranah GJ, Chan AT, Giovannucci E, Ma J, Fuchs C, et al. (2005) Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses’ Health Study and the Physicians’ Health Study. Mol Carcinog 44: 21–30.
22. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, et al. (2005) A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 15: 535–546.
23. McGreavey LE, Turner F, Smith G, Boylan K, Timothy Bishop D, et al. (2005) No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics 15: 713–721.
24. Samowitz WS, Wolff RK, Cartin K, Sweeney C, Ma KN, et al. (2006) Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drug use in colorectal cancer prevention. Clin Gastroenterol Hepatol 4: 894–901.
25. Liao LH, Zhang H, Lai MP, Lai KW, Lai AK, et al. (2007) The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese. Clin Chim Acta 380: 191–196.
26. Kury S, Buecher B, Robiou-du-Pont S, Scoul C, Seballe V, et al. (2007) Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev 16: 1460–1467.
27. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey AB, et al. (2006) Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 17: 3098–3107.
28. Buyukdogan M, Boruban MC, Artac M, Demirel S (2009) Frequency of Cytochrome 450 (CYP2C9 and CYP2C19) genetic polymorphisms in patients with colorectal carcinoma. Int J Hemato Oncol 19: 134–139.
29. Northwood EL, Elliott F, Forman D, Barrett JH, Wilkie MJ, et al. (2010) Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics 20: 315–326.
30. Cleary SP, Cotterchio M, Shi E, Gallinger S, Harper P (2010) Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Ann J Epidemiol 172: 1000–1014.
31. Sautz J, Rudolph A, Hein R, Hoffmeister M, Buch S, et al. (2011) Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer 18: 265–276.
32. Xiong Y, Wang M, Fang K, Xing Q, Feng G, Shen L, He L, Qin S (2011) A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. Genomics 97: 277–281.
33. Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, et al (1998) Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Lys359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenet Genomics 8: 365–373.
34. Zhou SF, Zhou ZW, Yang LP, Cai JP (2009) Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 16: 3480–3675.